Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 13
Submit an article Journal homepage
583
Views
0
CrossRef citations to date
0
Altmetric
Articles

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

Hussein A. Abbasa Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;b Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;c Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;d Department of Hematology and Medical Oncology, The University of Texas Health Science Center, Houston, TX, USACorrespondence[email protected]
View further author information
,
Edward Ayouba Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0003-1321-0114View further author information
ORCID Icon,
Hanxiao Suna Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;e Department of Biostatistics, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Rashmi Kanagal-Shamannaf Department of Hematopathology, Division of Pathology-Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-7829-5249View further author information
ORCID Icon,
Nicholas J. Shorta Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-2983-2738View further author information
ORCID Icon,
Ghayas Issaa Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-4339-8683View further author information
ORCID Icon,
Musa Yilmaza Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-4498-4895View further author information
ORCID Icon,
Sherry Piercea Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Daniel Riveraa Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Brent Chamg Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX, USAView further author information
,
Shane Wingg Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX, USAView further author information
,
Ziyi Lie Department of Biostatistics, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Danielle Hammonda Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Elias Jabboura Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Gautam Borthakura Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-7679-6453View further author information
ORCID Icon,
Guillermo Garcia-Maneroa Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Michael Andreeffa Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Naval Davera Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-7103-373XView further author information
ORCID Icon,
Tapan Kadiaa Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Marina Konoplevaa Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Courtney DiNardoa Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-9003-0390View further author information
ORCID Icon &
Farhad Ravandia Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-7621-377XView further author information
ORCID Icon show all
Pages 3105-3116 | Received 14 Jun 2022, Accepted 19 Aug 2022, Published online: 10 Sep 2022

References

  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an International Expert Panel. Blood. 2017;129(4):424–447.
  • Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
  • Petit P, Alexander M, Fondu P. Letter: monosomy 7 in erythroleukaemia. Lancet. 1973;2(7841):1326–1327.
  • Rowley JD. Letter: deletions of chromosome 7 in haematological disorders. Lancet. 1973;2(7842):1385–1386.
  • Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92(7):2322–2333.
  • Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114–2121.
  • Hussain FT, Nguyen EP, Raza S, et al. Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications. Am J Hematol. 2012;87(7):684–686.
  • Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago Series. Blood. 2003;102(1):43–52.
  • Han SY, Mrózek K, Voutsinas J, et al. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021;5(10):2481–2489.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • Kalwinsky DK, Raimondi SC, Schell MJ, et al. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol. 1990;8(1):75–83.
  • Poiré X, Labopin M, Polge E, et al. Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. Am J Hematol. 2019;94(2):231–239.
  • McNerney ME, Brown CD, Peterson AL, et al. The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q). Br J Haematol. 2014;166(4):550–556.
  • Hartmann L, Haferlach C, Meggendorfer M, et al. Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations. Genes Chromosomes Cancer. 2019;58(10):698–704.
  • Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2004;22(16):3432–3433.
  • Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99(3):465–473.
  • Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol. 2010;2(6):a000919.
  • Killock D. Venetoclax in AML: efficacy confirmed. Nat Rev Clin Oncol. 2020;17(10):592.
  • Pollyea DA, Pei S, Stevens BM, et al. The intriguing clinical success of BCL-2 inhibition in acute myeloid leukemia. Annu Rev Cancer Biol. 2021;5(1):277–289.
  • Kim K, Maiti A, Loghavi S, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127(20):3772–3781.
  • Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia. 1988;2(7):403–412.
  • El-Menoufy MAM, Mourad ZI, Farahat NM. The prognostic impact of loss of chromosome 7 material detected by fluorescence in situ hybridization (FISH) in myeloid malignancies. J Egypt Natl Canc Inst. 2018;30(4):133–138.
  • Gardin C, Pautas C, Fournier E, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020;4(9):1942–1949.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.